表紙
市場調査レポート

EpiCast Report:強直性脊椎炎の疫学予測

EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2024

発行 GlobalData 商品コード 298494
出版日 ページ情報 英文 58 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
EpiCast Report:強直性脊椎炎の疫学予測 EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2024
出版日: 2015年08月01日 ページ情報: 英文 58 Pages
概要

強直性脊椎炎は、全身性、慢性、進行性の炎症性関節炎で、最も一般的なリウマチ性疾患の1つとして認識されています。世界の主要7ヶ国(米国、フランス、ドイツ、イタリア、スペイン、英国、日本)における強直性脊椎炎の有病者数は、ベースラインシナリオでは2014年の106万7,905人から、2024年には127万9,010人まで増加すると予測されています。

当レポートでは、世界の主要7ヶ国における強直性脊椎炎について取り上げ、危険因子の概要と世界の動向、疫学予測、疫学レポート、疾患動向の分析を提供しております。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界的な動向
    • 米国
    • EU5ヶ国
    • 日本
  • 予測手法
    • AS有病診断に利用した情報源
    • Nr-axSpA 有病診断に利用した情報源
    • AS診断におけるHLA-B27血清反応陽性の有病率計算に利用した情報源
    • AS有病診断に利用しなかった情報源
    • 予測の前提条件と手法(ベースラインおよび代替シナリオ)
  • 強直性脊椎炎の疫学予測-ベースラインシナリオ
    • 診断された有病者数
    • 診断された有病者数:年齢別
    • 診断された有病者数:性別
    • 診断された有病率:年齢標準化
    • 診断されたNr-axSpA 有病者数
    • HLA-B27血清反応陽性の有病率
  • 強直性脊椎炎の疫学予測-代替シナリオ
    • 診断されたAS有病者数
    • 診断されたNr-axSpA有病者数
  • 議論
    • 疫学動向に関する結論
    • 分析の限界
    • 分析の強み

第4章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHCER056-15

Ankylosing spondylitis (AS) - a systemic, chronic, and progressive inflammatory arthritis, is the prototype of a family of related disorders known as seronegative spondyloarthritis (SpA) and one of the most common rheumatic diseases across the globe. AS primarily affects the spine and sacroiliac (SI) joints and progresses into severe inflammation that fuses the spine, leading to permanent painful stiffness of the back. AS that occurs before any structural changes in the spine is referred to as non-radiographic axial spondyloarthritis (nr-axSpA) which is the early stage of AS. Some of non-radiographic axial spondyloarthritis progress to AS and some do not.

GlobalData's epidemiological analysis provides a country-specific forecast for the diagnosed prevalent cases of AS in the 7MM during 2014-2024. GlobalData epidemiologists made sure all the country-specific studies report diagnosed prevalent cases of AS, diagnosed prevalent cases of nr-axSpA, and HLA-B27 seropositivity cases in diagnosed AS cases based on medical chart review by a physician or data extracted from national registries. GlobalData epidemiologists provide a forecast for the diagnosed prevalent cases of AS and nr-axSpA using two different approaches: 1) forecasting the diagnosed prevalent cases of AS and nr-axSpAusing data obtained from peer reviewed journal articles and 2) forecasting the diagnosed prevalent cases of AS and nr-axSpA by applying a trend based on data obtained from primary research to the diagnosed prevalent cases calculated using the base scenario. The forecast methodology was consistent across all the 10MM to allow for a meaningful comparison among them.

The diagnosed prevalent cases of AS in the 7MM in the base scenario increased from 1,045,903 diagnosed prevalent cases in 2014 to 1,067,905 diagnosed prevalent cases in 2024, with an annual growth rate (AGR) of 0.21%. The forecast in the alternate scenario based on primary research data showed that there will be a substantial increase in the diagnosed prevalent cases of AS in the 7MM from 1,279,010 diagnosed prevalent cases in 2014 to 2,230,825 diagnosed prevalent cases in 2024, at an AGR of 7.44%. The forecast methodology was consistent across all the 10MM to allow for a meaningful comparison among them.

Scope

  • The Ankylosing Spondylitis EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for ankylosing spondylitis (AS) in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, Japan). It includes a 10-year epidemiological forecast of the diagnosed prevalent cases of ankylosing spondylitis segmented by sex, age (in ten-year increments beginning at 15 years and ending at =65 years), and diagnosed prevalent cases of non-radiographic axial spondyloarthritis, and diagnosed prevalent cases of AS segmented by HLA-B27 seropositivity status in these markets.
  • The ankylosing spondylitis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Ankylosing Spondylitis EpiCast series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global ankylosing spondylitis market.
  • Quantify patient populations in the global ankylosing spondylitis market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for ankylosing spondylitis therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used for Diagnosed Prevalence of AS
    • 3.4.2. Sources used for Diagnosed Prevalence of Nr-axSpA
    • 3.4.3. Sources Used for the Prevalence of HLA-B27 Seropositivity in Diagnosed AS
    • 3.4.4. Sources Not Used
    • 3.4.5. Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Base Scenario
    • 3.4.6. Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSpA - Base Scenario
    • 3.4.7. Forecast Assumptions and Methods, HLA-B27 Seropositivity in Diagnosed AS
    • 3.4.8. Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Alternative Scenario
    • 3.4.9. Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSp - Alternative Scenario
  • 3.5. Epidemiological Forecast for AS (2014-2024) - Base Scenario
    • 3.5.1. Diagnosed Prevalent Cases of AS
    • 3.5.2. Age-Specific Diagnosed Prevalent Cases of AS
    • 3.5.3. Sex-Specific Diagnosed Prevalent Cases of AS
    • 3.5.4. Age-Standardized Diagnosed Prevalence of AS
    • 3.5.5. Diagnosed Prevalent Cases of Nr-axSpA
    • 3.5.6. Prevalent Cases of HLA-B27 Seropositivity in Diagnosed AS Cases
  • 3.6. Epidemiological Forecast for AS (2014-2024) - Alternative Scenario
    • 3.6.1. Diagnosed Prevalent Cases of AS
    • 3.6.2. Diagnosed Prevalent Cases of Nr-axSpA
  • 3.7. Discussion
    • 3.7.1. Epidemiological Forecast Insight
    • 3.7.2. Limitations of the Analysis
    • 3.7.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Diagnostic Criterion for AS and Nr-axSpA
  • Table 2: Risk Factors and Comorbidities for AS
  • Table 3: Summary of the Global Reported Prevalence of AS
  • Table 4: Incidence of AS, Cases per 100,000 Population, 1935-1973, Rochester, Minnesota, US
  • Table 5: Annual Incidence of AS, Cases per 100,000 Population, 1980-1990, Finland
  • Table 6: 7MM, Sources of Diagnosed Prevalence Data for AS used in the Epidemiology Forecast
  • Table 7: 7MM, Sources of Diagnosed Prevalence Data for Nr-axSpA used in the Epidemiology Forecast
  • Table 8: 7MM, Sources of HLA-B27 Seropositivity Data in Diagnosed AS Cases used in the Epidemiology Forecast
  • Table 9: 7MM, Diagnosed Prevalent Cases of AS, Both Sexes, Ages ≥15 Years, Select Years, N, 2014-2024
  • Table 10: 7MM, Age-Specific Diagnosed Prevalent Cases of AS, Both Sexes, N (Row %), 2014
  • Table 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of AS, Ages ≥15 Years, N (Row %), 2014
  • Table 12: 7MM, Diagnosed Prevalent Cases of Nr-axSpA, Both Sexes, Ages ≥15 Years, Select Years, N, 2014-2024
  • Table 13: 6MM, Prevalent Cases of HLA-B27 Seropositivity in Diagnosed AS Cases, Both Sexes, Ages ≥15 Years, Select Years, N, 2014-2024
  • Table 14: 6MM, HLA-B27 and Non-HLA-B27 Seropositivity Status Among Diagnosed AS Cases, Both Sexes, Ages ≥15 Years, N, 2014
  • Table 15: 7MM, Diagnosed Prevalent Cases of AS, Both Sexes, Ages ≥15 Years, Select Years, N, 2014-2024
  • Table 16: 7MM, Diagnosed Prevalent Cases of Nr-axSpA, Both Sexes, Ages ≥15 Years, Select Years, N, 2014-2024

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of AS, Both Sexes, Ages ≥15 Years, N, 2014-2024
  • Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of AS, Both Sexes, N, 2014
  • Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of AS, Ages ≥15 Years, N, 2014
  • Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of AS, Cases per 100,000 Population, Men and Women, 2014
  • Figure 5: 7MM, Diagnosed Prevalent Cases of Nr-axSpA , Both Sexes, Ages ≥15 Years, N, 2014-2024
  • Figure 6: 6MM, Prevalent Cases of HLA-B27 Seropositivity in Diagnosed AS Cases, Both Sexes, Ages ≥15 Years, N, 2014-2024
  • Figure 7: 6MM, HLA-B27 and Non-HLA-B27 Seropositivity Status Among Diagnosed AS Cases, Both Sexes, Ages ≥15 Years, N, 2014
  • Figure 8: 7MM, Diagnosed Prevalent Cases of AS, Both Sexes, Ages ≥15 Years, N, 2014-2024
  • Figure 9: 7MM, Diagnosed Prevalent Cases of Nr-axSpA, Both Sexes, Ages ≥15 Years, N, 2014-2024
Back to Top